Regeneron Pharmaceuticals, Inc. - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Regeneron Pharmaceuticals, Inc., covering the period ended June 30, 1998. Regeneron is a biotechnology company focused on discovering and developing novel therapeutics, primarily through collaborations with major pharmaceutical partners including The Procter & Gamble Company, Merck & Co., Inc., and Amgen Inc. The company has not yet generated revenue from commercial product sales.
Key Financial Metrics
| Metric | Q2 1998 | Q2 1997 | YTD 1998 | YTD 1997 |
|---|---|---|---|---|
| Total Revenue | $15.2 million | $6.6 million | $23.4 million | $12.8 million |
| Net Income (Loss) | $2.1 million | ($4.3 million) | ($1.7 million) | ($10.2 million) |
| EPS (Basic/Diluted) | $0.07 | ($0.16) | ($0.05) | ($0.38) |
| Cash & Equivalents | $22.5 million | $28.9 million (Dec '97) | $22.5 million | $51.4 million (Dec '97) |
| Total Assets | $165.1 million | $168.4 million (Dec '97) | $165.1 million | $168.4 million (Dec '97) |
| Accumulated Deficit | ($170.3 million) | ($168.6 million) | ($170.3 million) | ($168.6 million) |
Liquidity: As of June 30, 1998, the company held $117.4 million in cash, cash equivalents, and marketable securities. The company has no established banking arrangements for short-term financing or lines of credit.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased significantly in Q2 1998 compared to Q2 1997, driven by a $5.0 million research progress payment from Procter & Gamble (P&G) and increased contract manufacturing revenue from Merck.
- Profitability: The company reported a net income of $2.1 million in Q2 1998, a reversal from the $4.3 million net loss in the same period in 1997. However, the company remained in a net loss position for the six-month period ($1.7 million loss vs. $10.2 million loss in 1997).
- Expense Trends: Research and development (R&D) expenses increased to $9.1 million in Q2 1998 from $6.9 million in Q2 1997 due to additional employees and increased clinical/preclinical activity. Conversely, the loss attributed to the Amgen-Regeneron Partners joint venture decreased to $0.2 million from $0.5 million.
- Cash Flow: Net cash used in operating activities was $8.7 million for the six months ended June 30, 1998, compared to $7.5 million in the prior year period. Investing activities provided $3.1 million in cash, primarily from the net sale of marketable securities.
Outlook, Risks, and Management Commentary
- Collaboration Milestones: Regeneron expects to receive a $5.0 million milestone payment from Sumitomo Pharmaceuticals in the third quarter of 1998 related to BDNF development in Japan. The company also anticipates potential future payments from P&G totaling up to $100 million or more through mid-2002.
- Product Development:
- AXOKINE: Collaboration with P&G aims to file an Investigational New Drug (IND) application in early 1999 for obesity treatment. Independent development for retinal diseases is also planned for early 1999.
- BDNF/NT-3: The Amgen-Regeneron partnership is advancing BDNF for ALS (Phase II planned) and NT-3 for enteric neuropathies (Phase I initiated).
- Risks: The company faces substantial risks regarding the failure of clinical trials, regulatory approval delays, and the potential termination of key collaboration agreements. There is no assurance that product candidates will be safe, effective, or approved for marketing.
- Intellectual Property: The company resolved patent interference proceedings with Amgen regarding CNTF and AXOKINE in March 1998 via a covenant not to sue.
- Year 2000 Issues: Management believes no material Year 2000 issues exist for computer systems, though analysis of embedded systems in laboratory equipment is ongoing.
Investor Verification Checklist
- Verify the timing and conditions for the expected $5.0 million milestone payment from Sumitomo Pharmaceuticals in Q3 1998.
- Monitor the status of the planned IND filing for AXOKINE with the FDA in early 1999.
- Assess the progress of the Amgen-Regeneron Partners Phase II clinical trial for BDNF in ALS patients.
- Review the company's cash burn rate relative to its $117.4 million liquidity position to confirm runway for operations.
- Confirm the status of the Rensselaer facility manufacturing validation for Merck products.